Question: 1101 

Evidence: This study was conducted from January 2016 to December 2018 in patients attending ART clinic in four health centers and Jinka Zonal Hospital. The nucleotide sequences discussed in this study were deposited into National Centre for Biotechnology Information (NCBI) GenBank under accession numbers MG570974-MG571084.

Rationale: The paper describes a study conducted between 2016 and 2018, and it reports new GenBank accession numbers for the sequences generated, indicating that the data being presented is from original research and has not been published before.

Answer: Yes

"""

Question: 1102 

Evidence: A cross-sectional study conducted on 253 adult patients attending ART clinics for ≥6 months in South Omo. Samples with VL ≥1000 copies/ mL were considered as virological failures (VF) and their reverse transcriptase gene codons 90–234 were sequenced using Illumina MiSeq.

Rationale: The paper explicitly states that the reverse transcriptase gene of HIV-1 from patient samples was sequenced, which means it reports HIV sequences.

Answer: Yes

"""

Question: 1103 

Evidence: The paper does not contain any description of in vitro passage experiments.

Rationale: A thorough review of the paper's content, including the abstract, introduction, methods, results, and discussion, finds no mention of in vitro passage experiments. The study is based on clinical samples from patients.

Answer: No

"""

Question: 1104 

Evidence: The paper does not contain any description of in vitro antiretroviral susceptibility testing.

Rationale: The methods and results sections describe genotypic resistance testing using sequencing and interpretation via the Stanford HIVdb. There is no mention of phenotypic assays, such as those that would determine IC50 values or fold-changes in susceptibility.

Answer: No

"""

Question: 2101 

Evidence: The nucleotide sequences discussed in this study were deposited into National Centre for Biotechnology Information (NCBI) GenBank under accession numbers MG570974-MG571084.

Rationale: The paper explicitly states the GenBank accession numbers for the sequences generated from the study's patient isolates.

Answer: Yes

"""

Question: 2102 

Evidence: The nucleotide sequences discussed in this study were deposited into National Centre for Biotechnology Information (NCBI) GenBank under accession numbers MG570974-MG571084.

Rationale: The paper only reports GenBank accession numbers for sequences obtained from the study participants (clinical isolates). There is no mention of sequencing any laboratory HIV isolates.

Answer: No

"""

Question: 2103 

Evidence: The nucleotide sequences discussed in this study were deposited into National Centre for Biotechnology Information (NCBI) GenBank under accession numbers MG570974-MG571084.

Rationale: The paper provides a specific range of GenBank accession numbers for the sequences it generated: MG570974 to MG571084.

Answer: MG570974-MG571084

"""

Question: 2202 

Evidence: Out of 41 genotyped isolates, 85.4% (35/41) had at least one ADR mutations on RT gene. Among NRTI resistance mutations, M184V (73.2%), and K219Q, (63.4%) were the most common resistance mutations detected from viraemic subjects, respectively.

Rationale: While the paper provides detailed tables and lists of mutations found in the study population (e.g., Table 2), it reports the prevalence of specific mutations across the cohort rather than providing a discrete, isolate-by-isolate list of mutations for each individual sequenced HIV isolate.

Answer: No

"""

Question: 2301 

Evidence: This study was conducted to investigate the drug resistance mutations and genetic diversity of HIV-1 in ART experienced patients in South Omo, Ethiopia.

Rationale: The paper consistently refers to the virus being studied as "HIV-1" throughout the text, and there is no mention of HIV-2 or other HIV species.

Answer: HIV-1

"""

Question: 2302 

Evidence: HIV-1 subtype C was the dominant, 87.8% (36/41), followed by inter-subtype recombinants strains BC (4.9%), M-09-CPX (4.9%), and BF1 (2.4%) were found.

Rationale: The results section explicitly lists the subtypes identified among the 41 sequenced isolates.

Answer: Subtype C, recombinant BC, M-09-CPX, BF1

"""

Question: 2303 

Evidence: Samples with VL ≥1000 copies/ mL were considered as virological failures (VF) and their reverse transcriptase gene codons 90–234 were sequenced using Illumina MiSeq.

Rationale: The methods section specifies that the region sequenced was the reverse transcriptase (RT) gene, covering codons 90–234. The RT gene is a part of the pol gene.

Answer: Reverse transcriptase (RT) gene (part of pol)

"""

Question: 2304 

Evidence: Samples with VL ≥1000 copies/ mL were considered as virological failures (VF) and their reverse transcriptase gene codons 90–234 were sequenced using Illumina MiSeq.

Rationale: The reverse transcriptase gene is a key component of the HIV pol gene. Sequencing the RT gene constitutes reporting results of HIV pol sequences.

Answer: Yes

"""

Question: 2401 

Evidence: This study was carried out in South Omo Zone of Southern Ethiopia bordering with Kenya in south and with South Sudan in southwest. A cross-sectional study was conducted from January 2016 to December 2018 in patients attending ART clinic in four health centers and Jinka Zonal Hospital.

Rationale: The study area and setting are clearly described as the South Omo Zone in Ethiopia.

Answer: South Omo, Ethiopia

"""

Question: 2402 

Evidence: A cross-sectional study was conducted from January 2016 to December 2018 in patients attending ART clinic in four health centers and Jinka Zonal Hospital.

Rationale: The study period during which samples were obtained is explicitly stated as January 2016 to December 2018.

Answer: 2016 to 2018

"""

Question: 2502 

Evidence: The available HIV drug resistance studies conducted in Ethiopia so far were based on the Standard Genotypic Resistance Testing (SGRT), that could not reliably detect clinically important low frequency (< 20%) drug resistance variant mutations of the virus quasispecies in a clinical sample. Currently, the emerging NGS platforms like Illumina MiSeq allow the detection of minority resistance mutation variants with 0.5–1% lower limit of detection while maintaining good accuracy.

Rationale: The paper contrasts previous Sanger-based studies with its own use of Next-Generation Sequencing (NGS), specifically the Illumina MiSeq platform. It does not mention using Sanger sequencing for its own data generation.

Answer: No

"""

Question: 2503 

Evidence: Samples with VL ≥1000 copies/ mL were considered as virological failures (VF) and their reverse transcriptase gene codons 90–234 were sequenced using Illumina MiSeq.

Rationale: The methods section explicitly states that sequencing was performed using the Illumina MiSeq platform, which is an NGS technology.

Answer: Yes

"""

Question: 2504 

Evidence: The paper does not contain any description of cloning samples prior to sequencing.

Rationale: The detailed methods for library preparation and sequencing for the Illumina MiSeq platform are described, and they involve amplifying the viral RNA directly to create a library for NGS, with no mention of a cloning step.

Answer: No

"""

Question: 2505 

Evidence: The paper does not contain any description of single genome sequencing.

Rationale: The methods describe a standard NGS approach on the Illumina MiSeq, which generates a population sequence from a bulk PCR product, not from individual, clonal genomes.

Answer: No

"""

Question: 2506 

Evidence: The paper does not contain any description of molecular cloning.

Rationale: The sequencing methodology is based on NGS of PCR amplicons without a cloning step. Terms like "cloning" or "clone" are not present in the paper's content.

Answer: No

"""

Question: 2601 

Evidence: Plasma was temporarily stored in multiple aliquots at −30°C at the study site and transported to Addis Ababa University and stored at −80°C, until shipped to Kampala, Uganda on dry ice for VL measurement and genotyping at Makerere University. HIV-1 genomic RNA was extracted from 140 µL of cryopreserved plasma.

Rationale: The paper explicitly states that viral RNA was extracted from plasma for both viral load measurement and genotyping, confirming that plasma virus sequencing was performed.

Answer: Yes

"""

Question: 2602 

Evidence: The paper does not contain any description of sequencing from PBMCs.

Rationale: The methods detail that RNA was extracted from plasma and that cDNA was generated from this RNA for sequencing. There is no mention of extracting DNA from PBMCs or sequencing proviral DNA.

Answer: No

"""

Question: 2603 

Evidence: From a total of 253 ART experienced study subjects, 47 (18.6%) showed VF (≥1000 copies/mL), of which 41 isolates were successfully sequenced on MiSeq platform.

Rationale: The paper states that 47 patients had virological failure, and sequencing was successfully performed on 41 of these plasma samples.

Answer: 41

"""

Question: 2604 

Evidence: The paper does not contain any description of sequencing from PBMCs.

Rationale: As no PBMC sequencing is mentioned, the number of such samples is zero.

Answer: 0

"""

Question: 2605 

Evidence: From a total of 253 ART experienced study subjects, 47 (18.6%) showed VF (≥1000 copies/mL), of which 41 isolates were successfully sequenced.

Rationale: The sequences were obtained from patients who were experiencing virological failure (VL ≥1000 copies/mL), which indicates active HIV replication.

Answer: Yes

"""

Question: 2606 

Evidence: The paper does not contain any description of sequencing from proviral DNA.

Rationale: The source material for sequencing was plasma RNA, as detailed in the methods. There is no indication that proviral DNA from cells was sequenced.

Answer: No

"""

Question: 2701 

Evidence: A total of 253 adults on first line ART for a median duration of 51 (IQR: 49–61) months were recruited from January 2016–December 2018.

Rationale: The study specifically recruited "adults" (age ≥18 years), and there is no mention of infants or children in the participant characteristics.

Answer: No

"""

Question: 2702 

Evidence: The paper does not describe the study as a clinical trial.

Rationale: The study is described as a cross-sectional study conducted in ART clinics. There is no mention of a clinical trial, intervention groups, or randomization.

Answer: No

"""

Question: 2703 

Evidence: The paper does not describe the study as a clinical trial.

Rationale: Since the study was not a clinical trial, it follows that not all individuals were in one.

Answer: No

"""

Question: 3101 

Evidence: A total of 253 adults on first line ART were recruited. From a total of 253 ART experienced study subjects, 47 (18.6%) showed VF (≥1000 copies/mL), of which 41 isolates were successfully sequenced.

Rationale: A total of 253 individuals had samples collected for the study. Of these, 47 met the criteria for virological failure and were thus candidates for sequencing.

Answer: 253

"""

Question: 3102 

Evidence: From a total of 253 ART experienced study subjects, 47 (18.6%) showed VF (≥1000 copies/mL), of which 41 isolates were successfully sequenced.

Rationale: Sequencing was only performed on the subset of patients who had virological failure (41 out of 253 total participants). Therefore, not all individuals underwent sequencing.

Answer: No

"""

Question: 4101 

Evidence: A total of 253 adults on first line ART for a median duration of 51 months were recruited. This study was conducted to investigate the drug resistance mutations and genetic diversity of HIV-1 in ART experienced patients.

Rationale: The paper explicitly states that all study participants were "ART experienced" and were "on ART". There is no mention of an ART-naive group.

Answer: No

"""

Question: 4102 

Evidence: This study was conducted to investigate the drug resistance mutations and genetic diversity of HIV-1 in ART experienced patients in South Omo, Ethiopia. A total of 253 adults on first line ART for a median duration of 51 months were recruited.

Rationale: The study's purpose and participant description confirm that all individuals had previously received and were currently on ARV drugs.

Answer: Yes

"""

Question: 4103 

Evidence: A total of 253 adults on first line ART for a median duration of 51 months were recruited.

Rationale: The paper only includes ART-experienced patients. There is no group of ART-naive individuals for comparison.

Answer: No

"""

Question: 4104 

Evidence: The paper does not contain any description of ART-naive individuals.

Rationale: As all participants were ART-experienced, the number of samples from ART-naive individuals is zero.

Answer: 0

"""

Question: 4105 

Evidence: Majority of them were females (60.5%), mean age was 33.5 years and 70% the study subjects were taking tenofovir (TDF) based ART, while 30% were on Zidovudine (AZT) based regimen during the study period.

Rationale: The paper provides general information about the ART regimens the participants were on (TDF or AZT based), but it does not claim to provide a complete, individualized ART history for every single participant in the study.

Answer: No

"""

Question: 4201 

Evidence: This study was conducted to investigate the drug resistance mutations and genetic diversity of HIV-1 in ART experienced patients.

Rationale: The study focuses on "acquired drug resistance" in patients who have been on ART, not on "transmitted drug resistance" which is found in ART-naive individuals.

Answer: No

"""

Question: 4202 

Evidence: This study was conducted to investigate the drug resistance mutations and genetic diversity of HIV-1 in ART experienced patients.

Rationale: Pretreatment HIV drug resistance refers to resistance in individuals before starting ART. This study exclusively involves individuals who are already on ART, so it does not report on pretreatment resistance.

Answer: No

"""

Question: 4301 

Evidence: Majority (71.9%) of them started ART in WHO III/IV stage, with the median base line CD4 count of 239. 70% the study subjects were taking tenofovir (TDF) based ART, while 30% were on Zidovudine (AZT) based regimen during the study period.

Rationale: The paper mentions that participants were on first-line ART, which typically consists of two NRTIs (like TDF or AZT) and one NNRTI. It specifies the NRTI backbone used but does not detail the specific NNRTI for all participants, though Efavirenz and Nevirapine are mentioned later in the context of resistance.

Answer: NRTIs (Tenofovir, Zidovudine), NNRTIs (Efavirenz, Nevirapine)

"""

Question: 4302 

Evidence: The paper does not mention integrase inhibitors.

Rationale: The drugs discussed are NRTIs and NNRTIs. There is no reference to integrase strand transfer inhibitors (INSTIs) like dolutegravir or raltegravir in the text.

Answer: No

"""

Question: 4303 

Evidence: The paper does not mention protease inhibitors.

Rationale: The study sequenced the reverse transcriptase gene and reported resistance mutations for NRTIs and NNRTIs. There is no mention of protease inhibitors or sequencing of the protease gene.

Answer: No

"""

Question: 4304 

Evidence: 70% the study subjects were taking tenofovir (TDF) based ART, while 30% were on Zidovudine (AZT) based regimen during the study period.

Rationale: The paper indicates that participants were on one of two different first-line ART regimen backbones (TDF-based or AZT-based), so they did not all receive the same ART.

Answer: No

"""

Question: 4305 

Evidence: The paper does not mention integrase inhibitors.

Rationale: Since integrase inhibitors are not mentioned at all in the paper, it can be inferred that the study participants did not receive them and were therefore INSTI-naive.

Answer: Yes

"""

Question: 4403 

Evidence: The paper does not provide specific data on how many individuals received more than one ART regimen.

Rationale: The participants are described as being on "first line ART". The paper does not provide details on whether any participants had previously been on a different regimen or had switched regimens.

Answer: NA

"""

Question: 4404 

Evidence: The paper does not provide specific data on how many individuals received more than two ART regimens.

Rationale: As above, the history of regimen changes is not detailed for the participants.

Answer: NA

"""

Question: 4405 

Evidence: The paper does not provide specific data on the number of ART regimens received by individuals.

Rationale: The paper lacks the necessary information to determine if all individuals received the same number of ART regimens.

Answer: NA

"""

Question: 4406 

Evidence: A total of 253 adults on first line ART were recruited.

Rationale: The paper describes all participants as being on "first line ART", which typically implies they are on their first regimen. However, it does not explicitly state that none had ever been on a second-line regimen.

Answer: NA

"""

Question: 4501 

Evidence: The paper does not mention dolutegravir.

Rationale: Dolutegravir is an integrase inhibitor, and the paper does not mention any integrase inhibitors.

Answer: 0

"""

Question: 4502 

Evidence: The paper does not mention darunavir.

Rationale: Darunavir is a protease inhibitor, and the paper does not mention any protease inhibitors.

Answer: 0

"""

Question: 5101 

Evidence: Out of 41 genotyped isolates, 85.4% (35/41) had at least one ADR mutations on RT gene.

Rationale: The results section provides the exact number and percentage of individuals with at least one drug resistance mutation.

Answer: 35

"""

Question: 5102 

Evidence: The paper does not mention integrase inhibitor resistance mutations.

Rationale: The study sequenced the reverse transcriptase gene and reported mutations associated with NRTI and NNRTI resistance. It did not sequence the integrase gene.

Answer: 0

"""

Question: 5103 

Evidence: Among NRTI resistance mutations, M184V (73.2%), K219Q (63.4%) and T215 (56.1%) complex were the most mutated positions.

Rationale: The paper reports various NRTI resistance mutations but does not specify a count for how many individuals had mutations specifically conferring resistance to Tenofovir (TDF). T215 complex mutations can contribute to TDF resistance, but a precise number of TDF-resistant cases is not provided.

Answer: NA

"""

Question: 5104 

Evidence: The paper does not mention integrase inhibitorQuestion: 5104 

Evidence: The paper does not mention integrase inhibitor resistance mutations.

Rationale: The study focused on sequencing the reverse transcriptase gene and reporting NRTI and NNRTI resistance mutations. There is no analysis or mention of the integrase gene or INSTI-resistance mutations.

Answer: None

"""

Question: 6101 

Evidence: The paper does not contain any description of phenotypic susceptibility testing.

Rationale: The methods and results sections are entirely focused on genotypic resistance testing using deep sequencing. There is no mention of phenotypic susceptibility tests being performed.

Answer: No

"""

Question: 6102 

Evidence: The paper does not contain any description of phenotypic susceptibility testing.

Rationale: Since no phenotypic testing was performed, the paper does not report IC50 or IC90 values.

Answer: No

"""

Question: 6103 

Evidence: The paper does not contain any description of phenotypic susceptibility testing.

Rationale: As no phenotypic testing was conducted, fold-change values (like IC50 fold change) are not reported.

Answer: No

"""

Question: 6104 

Evidence: The paper does not contain any description of phenotypic susceptibility testing.

Rationale: The paper exclusively used genotypic methods (Illumina MiSeq sequencing and Stanford HIVdb interpretation). No phenotypic susceptibility assay is mentioned.

Answer: None

"""

Question: 6105 

Evidence: The paper does not contain any description of replication capacity assays.

Rationale: The study's focus is on genetic diversity and genotypic drug resistance. There is no mention of experiments measuring viral replication capacity.

Answer: No

"""

Question: 6106 

Evidence: The paper does not contain any description of phenotypic susceptibility testing.

Rationale: Since phenotypic testing was not performed, no drugs were tested using such an assay.

Answer: None

"""

Question: 7101 

Evidence: The paper does not contain any description of site-directed mutagenesis.

Rationale: All viral sequences were obtained directly from patient plasma samples. The study did not involve the engineering of viruses with specific mutations in the laboratory.

Answer: No

"""

Question: 7102 

Evidence: The paper does not contain any description of in vitro passage experiments.

Rationale: The paper describes a clinical study of patients on ART. There is no mention of passaging viruses in cell culture in a laboratory setting.

Answer: No

"""